Impact of COVID-19 on Cardiovascular and Diabetic Patients

COVID-19 has impacted the world’s health systems in ways that have not been seen before, with deaths and infections affecting millions of people in the world today. The virus is especially dangerous for the most vulnerable groups of the population, for instance, patients with CVD and diabetes. Not only do these persons need to understand their susceptibility to more severe forms should they be infected by the SARS-CoV-2 virus, which is responsible for COVID-19, but they also have to be aware of the fact that their conditions present specific treatment challenges. Knowledge of COVID-19’s effects and its interactions with these chronic illnesses is vital in caring for the patients and in catering for the impacts on available healthcare resources during the pandemic.

COVID-19 is a serious threat to patients with cardiovascular disease. This infection can also make pre-existing heart conditions worse to the point of heart failure, arrhythmias, and acute coronary syndromes. People with pre-existing heart issues are more vulnerable to poor evolution based on how the virus increases inflammation in the heart. This inflammation can result in the rupture of the plaques, and this makes people suffer heart attacks and other cardiovascular complications. Also, COVID-19 can exert a direct impact on the respiratory system, resulting in pulmonary hypertension, which puts more pressure on the heart, especially for patients with pre-existing cardiovascular disorders.

Likewise, COVID-19 impacts those having diabetes in dreadful ways; they form a vulnerable population during the pandemic. Diabetes can affect the immune system of a person to some extent; therefore, the body may not be very strong enough to fight off infections such as COVID-19. Also, high blood sugar affects inflammation processes and, if infected, can lead to more serious complications. Also, diabetic patients have other related illnesses like obesity, hypertension, and cardiovascular disease, which elevates the chances of critical illness and death caused by COVID-19. Diabetic patients who get infected with COVID-19 have to be closely monitored before and during management to ensure good glycemic control and proceed with appropriate management of any complications.

A new study record reveals that people with both CVD and diabetes are at a much higher risk of hospitalization, ICU admission, and death if infected with COVID-19. These observations signify that more effective approaches to the allocation and utilization of resources concerning these identified populations are vital and urgent. Patient compliance with prescribed drugs means good management of clients, including maintaining near-normal blood sugar and blood pressure levels, preventing diseases by getting vaccinated, and washing hands frequently.

COVID-19 and cardiovascular disease can coexist and affect each other in various ways. COVID-19 is proprioceptively linked with the ACE2 receptor, which is also used by the virus to invade human cells and at the same time control blood pressure and cardiovascular functions. SARS-CoV-2 uses this receptor to enter cells; this interferes with usual cardiovascular processes and causes complications. For instance, the direct viral tropism for ACE2 causes unopposed intravascular angiotensin II activity, leading to constriction, inflammation, and oxidative stress, all of which are cardiotoxic.

Yearwise Publication Trend on cardiovascular disease

Find publication trends on relevant topics

Patients with heart failure should be more alert since they are more vulnerable. COVID-19 can cause acute decompensated heart failure, where the patient becomes extremely unwell and needs to see a doctor urgently. A cytokine storm provoked by the virus entails elevated levels of pro-inflammatory cytokines that can worsen the condition of heart failure and cause critical states. Also, COVID-19 deteriorates the patient’s coagulation status, which leads to the formation of blood clots and blocks of some organs, for example, thromboembolism or stroke, dangerous in patients with prior cardiovascular diseases.

This situation makes winding up the COVID-19 complications even more severe for diabetic patients due to other metabolic complications they may be facing. High blood sugar levels such as those seen in diabetes can weaken immune systems and consequently make the body more vulnerable to infections. Further, in the context of an inflammation state linked to diabetes, the

severity of COVID-19 can become even worse. Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are two severe metabolic complications that appear in diabetic patients with COVID-19, for which early management would be essential due to high mortality.

The strategy of dealing with COVID-19 cases in patients with diabetes is not a one-size-fits-all approach. It is also crucial to maintain proper glycemic levels; in a case where diabetes is present, it is associated with a poor prognosis. Diabetes patients should be encouraged to check their blood glucose levels regularly and modify their medications with the doctor’s help. Furthermore, concerning patients with T2DM, healthcare providers should monitor the development of DKA and HHS and act accordingly when possible.

As part of the REPROGRAM consortium, researchers have pointed out that such patient groups require specific intervention approaches during the COVID-19 pandemic. Such strategies include the restructuring of the health care systems to ensure continuity of care to patients with chronic diseases in case of lockdowns or congestion of the health care centers. Telemedicine has thus become very useful in such a situation as it enables monitoring and consultation from the comfort of clients’ homes, thus minimizing their exposure to the virus.

Recent Publications on cardiovascular disease

Find publications on relevant topics

The more vulnerable patients are also at risk of contracting the disease; therefore, preventive measures are important. Immunization against COVID-19 is advised for persons who have cardiovascular disease and diabetes. Such patients should also ensure they observe the preventive measures as recommended by the authorities, which include wearing masks, observing social distancing, and washing hands frequently. Thus, in addition to the protection of oneself and family members, society as a whole must limit contact with high-risk groups and adhere to the instructions given by public health officials to prevent the spread of the virus.

Therefore, COVID-19 poses a severe risk to patients with cardiovascular diseases and diabetes; thus, care should be extensive and preemptive for patients with these conditions. Awareness of the particular characteristics observed in the identified populations may help design corresponding intervention measures to optimize patient care and improve the results in these cases. In future utilization of these examined strategies as well as in the search for other suitable interventions, future research and practice will be imperative as the pandemic persists to ensure optimal care for at-risk populations.

References

  1. Rahman J, Muralidharan A, Quazi SJ, Saleem H, Khan S. Neurological and Psychological Effects of Coronavirus (COVID-19): An Overview of the Current Era Pandemic. Cureus. 2020 Jun 5;12(6):e8460. doi: 10.7759/cureus.8460. PMID: 32528783; PMCID: PMC7282368.
  2. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020 Jun;92(6):552-555. doi: 10.1002/jmv.25728. Epub 2020 Mar 11. PMID: 32104915; PMCID: PMC7228394.
  3. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 Jun 1;77(6):683-690. doi: 10.1001/jamaneurol.2020.1127. PMID: 32275288; PMCID: PMC7149362.
  4. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19. PMID: 32075877; PMCID: PMC7164637.
  5. Bhaskar S, Rastogi A, Chattu VK, Adisesh A, Thomas P, Alvarado N, Riahi AD, Varun CN, Pai AR, Barsam S, Walker AH. Key Strategies for Clinical Management and Improvement of Healthcare Services for Cardiovascular Disease and Diabetes Patients in the Coronavirus (COVID-19) Settings: Recommendations From the REPROGRAM Consortium. Front Cardiovasc Med. 2020 Jun 16;7:112. doi: 10.3389/fcvm.2020.00112. PMID: 32613010; PMCID: PMC7308556.
  6. Verma S, Dhanak M, Frankenfield J. Visualizing the effectiveness of face masks in obstructing respiratory jets. Phys Fluids (1994). 2020 Jun 1;32(6):061708. doi: 10.1063/5.0016018. PMID: 32624649; PMCID: PMC7327717.
  7. Xiao J, Shiu EYC, Gao H, Wong JY, Fong MW, Ryu S, Cowling BJ. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-Personal Protective and Environmental Measures. Emerg Infect Dis. 2020 May;26(5):967-975. doi: 10.3201/eid2605.190994. Epub 2020 May 17. PMID: 32027586; PMCID: PMC7181938.
  8. Cowling BJ, Leung GM. Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak. Euro Surveill. 2020 Feb;25(6):2000110. doi: 10.2807/1560-7917.ES.2020.25.6.2000110. Epub 2020 Feb 11. PMID: 32046814; PMCID: PMC7029449.
  9. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29. PMID: 31995857; PMCID: PMC7121484.
  10. Shiu EYC, Leung NHL, Cowling BJ. Controversy around airborne versus droplet transmission of respiratory viruses: implication for infection prevention. Curr Opin Infect Dis. 2019 Aug;32(4):372-379. doi: 10.1097/QCO.0000000000000563. PMID: 31259864.

Top Experts on “cardiovascular disease